Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
An erratum to this article was published (Diabetes Obes Metab, Mar 2025 ↗)
Authors' conclusion
Semaglutide 2.4 mg significantly improved physical functioning, with greater proportions of participants achieving MWPC compared with placebo, and showed beneficial effects on WRQOL and HRQOL beyond physical functioning.
Study context
- Population
- Individuals with overweight/obesity
- Comparison
- Semaglutide 2.4 mg vs placebo
- Primary endpoint
- Physical functioning (confirmatory secondary endpoint): change from baseline in IWQOL-Lite-CT (STEP 1 and 2) and SF-36v2 (STEP 1-4) scores
- Follow-up
- Week 68
Methodological detailsPhase 3a, double-blind, 68-week
- Phase 3a
- Double-blind
- 68-week
Primary result
As reported in the abstract
- IWQOL-Lite-CT Physical Function meaningful within-person change (MWPC), STEP 1: semaglutide 2.4 mg vs placebo
- 51.8% vs. 28.3%; p < 0.0001
- IWQOL-Lite-CT Physical Function MWPC, STEP 2: semaglutide 2.4 mg vs placebo
- 39.6% vs. 29.5%; p = 0.0083
- SF-36v2 Physical Functioning MWPC, STEP 1: semaglutide 2.4 mg vs placebo
- 39.8% vs. 24.1%; p < 0.0001
- SF-36v2 Physical Functioning MWPC, STEP 2: semaglutide 2.4 mg vs placebo
- 41.0% vs. 27.3%; p = 0.0005
- SF-36v2 Physical Functioning MWPC, STEP 4: semaglutide 2.4 mg vs placebo
- 18.0% vs. 6.6%; p < 0.0001
Secondary outcomes
Other IWQOL-Lite-CT and SF-36v2 scale scores · Week 68
- All other scale scores in STEP 1-4 numerically improved with semaglutide 2.4 mg vs placebo, except SF-36v2 Role Emotional in STEP 2
Original publication
Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials. Diabetes Obes Metab. Published 2 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →